Royal Bank of Canada Has $30.52 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Royal Bank of Canada trimmed its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 26.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 204,056 shares of the company's stock after selling 73,533 shares during the quarter. Royal Bank of Canada owned about 0.25% of DaVita worth $30,516,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of DVA. Nisa Investment Advisors LLC increased its position in DaVita by 10.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 40,500 shares of the company's stock worth $6,057,000 after buying an additional 3,680 shares during the last quarter. Janney Montgomery Scott LLC increased its position in DaVita by 1.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 25,020 shares of the company's stock worth $3,742,000 after buying an additional 429 shares during the last quarter. Secure Asset Management LLC acquired a new position in DaVita during the fourth quarter worth $208,000. Impact Partnership Wealth LLC increased its position in DaVita by 3.7% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after buying an additional 70 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after acquiring an additional 68 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Performance

Shares of NYSE DVA traded down $1.02 during mid-day trading on Thursday, hitting $135.65. The company had a trading volume of 295,451 shares, compared to its average volume of 821,872. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business's 50-day simple moving average is $144.67 and its 200-day simple moving average is $153.13. DaVita Inc. has a 12 month low of $131.76 and a 12 month high of $179.60. The firm has a market cap of $10.24 billion, a P/E ratio of 12.63, a PEG ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The business had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter last year, the company earned $2.26 earnings per share. The firm's revenue was up 5.0% on a year-over-year basis. As a group, analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

DVA has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Finally, Truist Financial decreased their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, DaVita has a consensus rating of "Hold" and an average target price of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.